Categories
Blood Cancer

Fixed-duration vs continuous therapy in CLL [Video]

Arnon Kater, MD, PhD, University of Amsterdam, Amsterdam, Netherlands, compares defined duration versus continuous therapy in chronic lymphocytic leukemia (CLL), commenting on the possibility of finding biomarkers to define the length and intensity of treatment for each patient, and highlighting promising results from the HOVON-141/VISION trial (NCT03226301). This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Categories
Blood Cancer

The role of measuring MRD in CLL [Video]

Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, describes using minimal residual disease (MRD) monitoring in treating chronic lymphocytic leukemia (CLL). Measuring MRD levels can enable accurate assessment of patients responses to treatment and can accordingly adjust treatment levels. MRD monitoring can additionally predict outcomes to chemoimmunotherapy and certain targeted therapies and Dr Niemann emphasizes the need to create MRD-guided regiments as in the Phase II HOVON-141/VISION trial (NCT03226301). This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.

Categories
Blood Cancer

HOVON 141/VISION: MRD guided time-limited treatment in CLL [Video]

Carsten Niemann, MD, PhD, Copenhagen University Hospital, Copenhagen, Denmark, presents results from the prospective, randomized Phase II HOVON-141/VISION trial (NCT03226301), which assessed time-limited venetoclax and ibrutinib for patients with relapsed/refractory chronic lymphocytic leukemia (CLL). Patients reaching undetectable minimal residual disease (MRD) after venetoclax and ibrutinib either received maintenance ibrutinib or stopped treatment, and all patients who failed to reach MRD status received maintenance ibrutinib. MRD guided time-limited treatment was proven to be beneficial, where the primary endpoint of progression-free survival (PFS) was met. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.